



CORDIAL

AN UPDATE FROM US

We are delighted to share with you the most recent achievements of our project

CORDIAL PROGRESS IN CLINICAL TRIALS

The European CORDIAL project is investigating the safety and efficacy of an innovative peritoneal dialysis (PD) system for renal patients.

The system relies on a device designed to continuously regenerate dialysate, enhancing clearance while minimizing both the volume of fluid needed and the adverse effects associated with elevated glucose concentrations.

A "First in Human" (FIH) trial started in 2024, enrolling a total of six patients to date in Utrecht (Netherlands), two in Modena (Italy), and four in Madrid (Spain), all of whom used it for two weeks, resulting in a total of 12 patients. The device has been well tolerated by patients, easy for healthcare professionals to use, and has shown promising early results.



JOIN US IN SHAPING THE FUTURE OF PD

The preliminary findings of the survey aimed at understanding the interests and concerns of PD patients regarding new devices are currently under analysis. Initial results will be released shortly.

The **survey** is still open to those interested in sharing their perspective. If you would like to participate, please visit the **CORDIAL** website.



WE DISSEMINATE OUR ADVANCEMENTS

In 2025, the device has been showcased at various national and international events, including the **"Controversies Conference on Green Dialysis: Environmentally Sustainable Care, Growth, and Innovation – KDIGO"** (DE, April), a course on **Therapeutic Innovations in Nephrology** (ES, April), the **EuroPD congress** (ES, October), and the **Annual Congress of European Society of Artificial Organs** (NL, June), among others.

An upcoming economic publication will provide an analysis of the European landscape and assess regional availability of PD. Other scientific articles published this year include an **update on portable, wearable and implantable artificial kidneys**, a **validation of computational PD models in animals and patients**, **recent advances in sorbent-based PD technologies**, and **the rationale and design of the first-in-human CORDIAL clinical trial on sorbent-assisted continuous flow PD**.



REACHING DESTINATION

Reaching patients in everyday clinical settings is our final destination, so we continue advancing on the path to CE marking.

Furthermore, to gain insights into the preferences and experiences of WEAKID users, focus groups have been established in the Netherlands, Spain and Italy.

We are receptive to collaborations with private partners, equity investors, or industry facilitators who are interested in accelerating commercialization.



Stay informed about our latest updates, or reach out to us at cordial@umcutrecht.nl.

MORE INFORMATION CAN BE FOUND ON OUR WEBSITE: www.projectcordial.eu

CORDIAL project started on the 1st of July 2021. It is a cooperation of nephrology departments of three European hospitals (UMC Utrecht (NL), UNIMORE (IT) and SERMAS (ES)) together with two companies (Nanodialysis (NL) and Ppi Healthcare Consulting (UK)).



UNIMORE
UNIVERSITÀ DEGLI STUDI DI
MODENA E REGGIO EMILIA



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945207